Innate Pharma Sa Quick Ratio (IPHA) starting from the fourth quarter 2025 to fourth quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Innate Pharma Sa  (NASDAQ: IPHA)

Innate Pharma Sa's Quick Ratio

IPHA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the fourth quarter 2025, Quick Ratio deteriorated to 0.77 a new company low.

Within Biotechnology & Pharmaceuticals industry 127 other companies have achieved higher Quick Ratio than Innate Pharma Sa in fourth quarter 2025. While Quick Ratio total ranking in the fourth quarter 2025 has deteriorated compared to the prior quarter from 0 to 2390.

Explain Quick Ratio?
How much Cash & cash equivalents IPHA´s has?
What are IPHA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IPHA Quick Ratio (Dec 31 2025)
Q4		 0
Q3		 0
Q2		 0
Q1		 (Dec 31 2024)
Q4
Y / Y Current Liabilities Change 11.12 % 11.12 % 11.12 % 11.12 % -16.79 %
Y / Y Cash & cash equivalent Change -57.69 % -57.69 % -57.69 % -57.69 % -5.96 %
Quick Ratio MRQ 0.77 0.77 0.77 0.77 2.01
IPHA's Total Ranking # 2390 # 0 # # #
Seq. Current Liabilities Change 0 % 0 % 0 % 11.12 % 0 %
Seq. Cash & cash equivalent Change 0 % 0 % 0 % -57.69 % 0 %



Quick Ratio fourth quarter 2025 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 128
Healthcare Sector # 729
Overall Market # 2390


Quick Ratio Statistics
High Average Low
3.01 1.8 0.77
(Dec 31 2020)   (Dec 31 2025)




Financial Statements
Innate Pharma Sa's Current Liabilities $ 41 Millions Visit IPHA's Balance sheet
Innate Pharma Sa's Cash & cash equivalent $ 31 Millions Visit IPHA's Balance sheet
Source of IPHA's Sales Visit IPHA's Sales by Geography


Cumulative Innate Pharma Sa's Quick Ratio

IPHA's Quick Ratio for the trailling 12 Months

IPHA Quick Ratio

 (Dec 31 2025)
12 Months		 0
12 Months		 0
12 Months		 0
12 Months		 (Dec 31 2024)
12 Months
Y / Y Current Liabilities TTM Growth 11.12 % 3.14 % -4.11 % -10.73 % -16.79 %
Y / Y Cash & cash equivalent TTM Growth -57.69 % -44.15 % -31.03 % -18.31 % -5.96 %
Quick Ratio TTM 0.77 1.05 1.36 1.68 2.01
Total Ranking TTM # 4600 # 0 # # #
Seq. Current Liabilities TTM Growth 2.57 % 2.63 % 2.7 % 2.78 % -4.8 %
Seq. Cash & cash equivalent TTM Growth -25.42 % -20.27 % -16.85 % -14.42 % -1.56 %

Quick ratio ranking by company, industry and sector >> Back to IPHA Financial Strength Comparisons >> Go to Compare IPHA Quick Ratio to its Competitors

On the trailing twelve months basis Due to unchanged in Current Liabilities in the Q4 2025 to $41.05 millions, cumulative Quick Ratio decreased to 0.77 below the Innate Pharma Sa average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Biotechnology & Pharmaceuticals industry 156 other companies have achieved higher Quick Ratio than Innate Pharma Sa. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2025 from 0 to 4600.

Explain Quick Ratio?
How much Cash & cash equivalents IPHA´s has?
What are IPHA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 157
Healthcare Sector # 988
Within the Market # 4600


trailing twelve months Quick Ratio Statistics
High Average Low
3.01 1.78 0.77
(Dec 31 2020)   (Dec 31 2025)




Companies with similar Quick Ratio in the quarter ending Dec 31 2025, within Biotechnology & Pharmaceuticals Industry Quick RatioDec 31 2025 MRQ Cash & cash equivalentDec 31 2025 MRQ Current Liabilities
Passage Bio Inc   2.01 $ 46.303  Millions$ 23.083  Millions
Dyadic International Inc   1.99 $ 7.321  Millions$ 3.687  Millions
Armata Pharmaceuticals Inc   1.98 $ 8.688  Millions$ 4.383  Millions
Regenxbio Inc   1.95 $ 230.070  Millions$ 118.095  Millions
Exozymes Inc   1.94 $ 3.039  Millions$ 1.567  Millions
Sutro Biopharma Inc   1.88 $ 141.428  Millions$ 75.133  Millions
Neurocrine Biosciences Inc   1.82 $ 1,480.400  Millions$ 811.400  Millions
Sana Biotechnology Inc   1.76 $ 138.382  Millions$ 78.726  Millions
Elutia Inc   1.75 $ 36.350  Millions$ 20.739  Millions
Tarsus Pharmaceuticals Inc   1.72 $ 233.627  Millions$ 135.695  Millions
Novavax inc   1.60 $ 735.084  Millions$ 459.950  Millions
Dbv Technologies S a   1.47 $ 127.100  Millions$ 86.450  Millions
Calidi Biotherapeutics Inc   1.42 $ 5.600  Millions$ 3.935  Millions
Autolus Therapeutics Plc  1.41 $ 104.289  Millions$ 73.840  Millions
Champions Oncology Inc   1.41 $ 9.785  Millions$ 6.939  Millions
Biocryst Pharmaceuticals Inc   1.40 $ 274.948  Millions$ 196.066  Millions
Coherus Oncology inc   1.23 $ 172.125  Millions$ 140.386  Millions
Lenz Therapeutics Inc   1.19 $ 25.179  Millions$ 21.187  Millions
Senti Biosciences Holdings Inc   1.18 $ 16.420  Millions$ 13.974  Millions
Alvotech  1.06 $ 172.359  Millions$ 163.045  Millions
Biocardia Inc   1.03 $ 2.496  Millions$ 2.432  Millions
Tradeup Acquisition Corp  1.00 $ 1.384  Millions$ 1.388  Millions
Bio techne Corp  0.92 $ 162.186  Millions$ 175.849  Millions
Ocugen Inc   0.81 $ 18.571  Millions$ 23.043  Millions
Quince Therapeutics Inc   0.79 $ 34.097  Millions$ 43.226  Millions
Scinai Immunotherapeutics Ltd  0.78 $ 1.661  Millions$ 2.116  Millions
Innate Pharma Sa  0.77 $ 31.463  Millions$ 41.047  Millions
Halozyme Therapeutics Inc   0.76 $ 133.820  Millions$ 177.092  Millions
Pelthos Therapeutics Inc   0.69 $ 17.973  Millions$ 25.993  Millions
Pluri Inc   0.64 $ 20.613  Millions$ 32.328  Millions

Date modified: 2026-09-18T13:11:06+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.